Enhancing tumor immunity using small molecules that target a specific receptor
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR
This study is looking at how a specific receptor in immune cells can be blocked to help boost the body's ability to fight cancer, with the goal of finding new treatments that could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-10895561 on NIH RePORTER |
What this research studies
This research investigates the role of the LPA5 receptor in CD8 cytotoxic T lymphocytes, which are crucial for fighting tumors. By identifying small molecule inhibitors that block LPA5, the research aims to enhance T cell activation and improve the immune response against cancer. The approach includes virtual and high-throughput screening of compounds to find effective inhibitors that can be developed into treatments. Patients may benefit from new therapies that boost their immune system's ability to combat cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that may benefit from enhanced T cell responses, such as melanoma or breast carcinoma.
Not a fit: Patients with cancers that do not involve CD8 T cell responses or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy options that significantly improve cancer treatment outcomes.
How similar studies have performed: Other research has shown promise in targeting immune checkpoints to enhance tumor immunity, suggesting that this approach could be effective.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Tigyi, Gabor J — University of Tennessee Health Sci Ctr
- Study coordinator: Tigyi, Gabor J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.